Loading clinical trials...

LowSalt4Life: A Mobile Application to Reduce Sodium Intake And Blood Pressure | Clinical Trials | Clareo Health

COMPLETEDNA

LowSalt4Life: A Mobile Application to Reduce Sodium Intake And Blood Pressure

A Just-In-Time Adaptive Mobile Application Intervention To Reduce Sodium Intake And Blood Pressure In Hypertensive Patients: LowSalt4Life

NCT05396001•University of Michigan

View on ClinicalTrials.gov

Summary

This research is being done to learn if a smartphone app with and without a just in time adaptive intervention (JITAI) can help patients with hypertension manage their sodium intake and improve their blood pressure.

Detailed Description

The primary and secondary outcomes will be determined in months 1 \& 2. Participants will continue for another 4 months and during that time data for exploratory measures will be collected. During the first 2 months of the study, a micro-randomized trial (MRT) will be performed within the App+JITAI group (N=200). This MRT is designed to learn which push notification messages effectively prompt the user to interact with the appropriate content within the mobile application.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosed with essential hypertension (HTN) by a medical provider and are on stable doses of antihypertensive therapy for at least three months prior to enrollment as documented in the electronic health record (EHR) and confirmed by participant self-report.
•2. A smartphone with a compatible Apple or Android operating system installed and able to download and use LowSalt4Life app including accepting all permissions and willing to allow the mobile applications to send push notifications
•3. A valid email address
•4. Fluent in spoken and written English

Exclusion Criteria

•1. Unstable symptoms or markedly elevated blood pressure (BP) at enrollment (defined as systolic BP\>180 mmHg, diastolic BP\>120 mmHg)
•2. Contraindication to a sodium restriction diet
•3. An estimated sodium intake less than 1,500mg per day
•4. Known secondary causes of HTN (e.g., adrenal insufficiency, pheochromocytoma)
•5. Estimated glomerular filtration rate (EGFR) \<30 or end-stage renal disease on dialysis
•6. Heart failure
•7. Inability to use Withings devices (blood pressure cuff and scale) due to equipment limitations or contraindications
•8. Currently pregnant or intent to become pregnant during the study period

Locations (1)

The University of Michigan

Ann Arbor, Michigan, United States

Key Dates

Start Date

August 15, 2022

Primary Completion Date

October 31, 2025

Completion Date

October 31, 2025

Last Updated

November 18, 2025

Enrollment

410

ACTUAL participants

Conditions

HypertensionBlood Pressure

Interventions

LowSalt4Life Application

BEHAVIORAL

Just-In-time Adaptive Intervention (JITAI)

BEHAVIORAL

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGNA

Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial

NCT07482930

Vagus Nerve StimulationsSpirometry+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LowSalt4Life: A Mobile Application to Reduce Sodium Intake And Blood Pressure

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart